Rucaparib for recurrent, locally advanced, or metastatic urothelial carcinoma (mUC): Results from ATLAS, a phase II open-label trial Meeting Abstract
| Authors: | Grivas, P.; Loriot, Y.; Feyerabend, S.; Morales-Barrera, R.; Teo, M. Y.; Vogelzang, N. J.; Grande, E.; Zakharia, Y.; Adra, N.; Alva, A. S.; Necchi, A.; Gupta, S.; Josephs, D. H.; Rodriguez-Vida, A.; Srinivas, S.; Wride, K.; Thomas, D.; Dusek, R.; Nepert, D. L.; Chowdhury, S. |
| Abstract Title: | Rucaparib for recurrent, locally advanced, or metastatic urothelial carcinoma (mUC): Results from ATLAS, a phase II open-label trial |
| Meeting Title: | 2020 Genitourinary Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 38 |
| Issue: | 6 Suppl. |
| Meeting Dates: | 2020 Feb 13-15 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2020-02-20 |
| Language: | English |
| ACCESSION: | WOS:000529525900469 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2020.38.6_suppl.440 |
| Notes: | Meeting Abstract: 440 -- Source: Wos |
